scispace - formally typeset
R

Rhiannon David

Researcher at AstraZeneca

Publications -  34
Citations -  820

Rhiannon David is an academic researcher from AstraZeneca. The author has contributed to research in topics: Carcinogen & Genotoxicity. The author has an hindex of 11, co-authored 29 publications receiving 510 citations. Previous affiliations of Rhiannon David include Imperial College London & University of Birmingham.

Papers
More filters
Journal ArticleDOI

Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development

TL;DR: It is found that the level of qualification of MPS-based assays for a given context of use and communication gaps between stakeholders are the major challenges slowing industrial adoption by end users, which in turn is causing a regulatory acceptance dilemma.
Journal ArticleDOI

Viral Vectors: The Road to Reducing Genotoxicity.

TL;DR: There is not a 'one size fits all' approach to vector modification for reducing genotoxicity, and addressing these challenges will be a key step in the development of therapies such as CRISPR-Cas9 and delivery of future gene-editing technologies.
Journal ArticleDOI

Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3

TL;DR: Colonic inflammation with the presence of IL6 associated with neoplastic tissue can alter metabolic competency of epithelial cells by manipulating CYP2E1 and CYP1B1 expression through transcriptional and epigenetic mechanisms, thus promoting colorectal carcinogenesis.
Journal ArticleDOI

Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis.

TL;DR: In this paper, a case-control study comparing women with polycystic ovarian syndrome (PCOS) to age and weight matched controls (n) without PCOS was performed, and miR-93 and miRNA-223 were determined by total RNA reverse transcription.